Navigation Links
Bioengineers develop bacterial strain to increase ethanol biofuel production
Date:12/10/2010

Georgia, US - A team of Bioengineers in the United States have modified a strain of bacteria to increase its ability to produce ethanol. The research, published in Biotechnology and Bioengineering, reveals how adaptation and metabolic engineering can be combined for strain improvement, a positive development for the biofuel industry.

The team focused their research on Zymomonas mobilis, a bacterium noted for its bio-ethanol producing potential. However, the team believed that ethanol production could be increased through improvement of xylose fermentation.

"Zymomonas mobilis is a superb ethanol producer with productivity exceeding yeast strains by several fold," said lead author Rachel Chen from the Georgia Institute of Technology. "In this study we sought to improve ethanol production by enhancing the ability of Z. mobilis to use and ferment xylose. Fermenting xylose at high concentration could in turn increase ethanol concentration, resulting in much improved productivity."

The team found that by metabolically altering the strain, sugar fermentation time was reduced from over 110 hours to about 35 hours. This improvement in fermentation allowed the strain to ferment higher concentrations of xylose.

"This demonstrated increase in fermentation and xylose utilization enabled us to produce ethanol to a concentration of 9% (w/v), the highest ever shown for this organism in mixed sugar fermentation," said Chen.

This research also investigated the underlying mechanism for the improvement. Interestingly, by adapting a strain in a high concentration of xylose, significant alterations of metabolism occurred.

One noticeable change was reduced levels of xylitol, a byproduct of xylose fermentation which can inhibit the strain's xylose metabolism. In addition, the first step of xylose metabolism, believed to be the rate-limiting step, was accelerated 4-8 times in the adapted strain, with the net effect of channeling xylose to ethanol instead of xylitol.

"This research illustrates the power of adaptation in strain improvement," concluded Chen. "This confirms that xylitol metabolism is the key to efficient use of xylose in this bacterium, which in turn can be vital for producing ethanol. This shows that adaptation is not only useful in improving strains, but is equally useful for pinpointing key bottlenecks in metabolically engineered strains."


'/>"/>

Contact: Ben Norman
Lifesciencenews@wiley.com
44-012-437-70375
Wiley-Blackwell
Source:Eurekalert

Related biology technology :

1. QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011
2. Shrink Nanotechnologies Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform
3. Shrink Nanotechnologies Enters Into Exclusive Development and Manufacturing Agreement With EV Group to Commercialize Stem Disc Platform
4. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
5. Pitt-led team develops nanoscale light sensor compatible with Etch-a-Sketch nanoelectronic platform
6. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
7. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
8. Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure
9. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
10. U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
11. Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):